Alexander I. Spira, MD, PhD, FACP - Breaking News in NSCLC: The Latest Evidence on Emerging Antibody Drug Conjugates Targeting TROP2

episode

CME in Minutes: Education in Oncology & Hematology not yet transcribed

▲ 0

Transcript

This episode hasn't been transcribed yet Upvotes decide what gets transcribed next — 0 so far. Sign in to upvote

Related

recent transcribed audio

Montreal Canadiens Play-by-Play Victor Findlay (9/24/26) 17 min · 24 Sep 2026 · Oilers NOW with Bob Stauffer

Could Tom Beat 100 8-Year-Olds? 22 min · 24 Sep 2026 · Wolf & Owl with Romesh Ranganathan and Tom Davis

BITESIZE | The Truth About Stress: How to Reduce Overwhelm & Feel Calmer Every Day | Dr Rangan Chatterjee #682 26 min · 24 Sep 2026 · Feel Better, Live More with Dr Rangan Chatterjee

The Wind in the Rose-Bush by Mary E Wilkins Freeman 1h 3m · 24 Sep 2026 · Classic Ghost Stories

H4 Mike Sando, The Kicker 44 min · 24 Sep 2026 · The Program

What A Time To Be Alive! - Marina Hyde [EXCLUSIVE EXTRACT] 56 min · 24 Sep 2026 · The Rest Is Entertainment

Report any issue

Source

Recorded05 Sep 2023

Publisherc.answersincme.com ↗

Handlerec:766069

Show notes

Please visit answersincme.com/DEV860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in lung cancer discusses TROP2-directed therapies for patients with non–small-cell lung cancer. Upon completion of this activity, participants should be better able to: Outline the rationale for incorporating TROP2-directed therapies into the treatment of patients with advanced NSCLC; Explain the latest clinical data supporting the use of emerging TROP2-directed therapies in the treatment of advanced NSCLC; and Identify strategies to maximize the incorporation of TROP2-directed therapies into treatment plans for patients with advanced NSCLC, as they become available.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Sign in